Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 4/2009

01-09-2009 | Original Article

Neuronal expression of copper transporter 1 in rat dorsal root ganglia: association with platinum neurotoxicity

Authors: Johnson J. Liu, Stephen M. F. Jamieson, Joshuan Subramaniam, Virginia Ip, Nancy N. Jong, Julian F. B. Mercer, Mark J. McKeage

Published in: Cancer Chemotherapy and Pharmacology | Issue 4/2009

Login to get access

Abstract

Purpose

We report the neuronal expression of copper transporter 1 (CTR1) in rat dorsal root ganglia (DRG) and its association with the neurotoxicity of platinum-based drugs.

Methods

CTR1 expression was studied by immunohistochemistry and RT-PCR. The toxicity of platinum drugs to CTR1-positive and CTR1-negative neurons was compared in DRG from animals treated with maximum tolerated doses of oxaliplatin (1.85 mg/kg), cisplatin (1 mg/kg) or carboplatin (8 mg/kg) twice weekly for 8 weeks.

Results

Abundant CTR1 mRNA was detected in DRG tissue. CTR1 immunoreactivity was associated with plasma membranes and cytoplasmic vesicular structures of a subpopulation (13.6 ± 3.1%) of mainly large-sized (mean cell body area, 1,787 ± 127 μm2) DRG neurons. After treatment with platinum drugs, the cell bodies of these CTR1-positive neurons became atrophied, with oxaliplatin causing the greatest percentage reduction in the mean cell body area relative to controls (42%; P < 0.05), followed by cisplatin (18%; P < 0.05) and carboplatin causing the least reduction (3.2%; P = NS). CTR1-negative neurons, with no immunoreactivity or only diffuse cytoplasmic staining, showed less treatment-induced cell body atrophy than CTR1-positive neurons.

Conclusions

CTR1 is preferentially expressed by a subset of DRG neurons that are particularly vulnerable to the toxicity of platinum drugs. These findings, together with its neuronal membrane localization, are suggestive of CTR1-related mechanisms of platinum drug neuronal uptake and neurotoxicity.
Literature
1.
2.
3.
4.
5.
Screnci D, McKeage MJ (1999) Platinum neurotoxicity: clinical profiles, experimental models and neuroprotective approaches. J Inorg Biochem 77:105–110PubMedCrossRef
6.
van der Gerritsen Hoop R, van der Burg MEL, ten Bokkel Huinink WW et al (1990) Incidence of neuropathy in 395 patients with ovarian cancer treated with or without cisplatin. Cancer 66:1697–1702CrossRef
7.
Machover D, Diaz-Rubio E, de Gramont A et al (1996) Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 7:95–98PubMed
8.
Canetta R, Rozencweig M, Carter SK (1985) Carboplatin: the clinical spectrum to date. Cancer Treat Rev 12(Suppl A):125–136PubMedCrossRef
9.
Albers J, Chaudhry V, Cavaletti G et al (2007) Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst Rev CD005228
10.
Daugaard GK, Petrera J, Trojaborg W (1987) Electrophysiological study of the peripheral and central neurotoxic effect of cis-platin. Acta Neurol Scand 76:86–93PubMedCrossRef
11.
Thompson SW, Davis LE, Kornfeld M et al (1984) Cisplatin neuropathy: clinical, electrophysiologic, morphologic, and toxicologic studies. Cancer 54:1269–1279PubMedCrossRef
12.
Krarup-Hansen A, Helweg-Larsen S, Schmalbruch H et al (2007) Neuronal involvement in cisplatin neuropathy: prospective clinical and neurophysiological studies. Brain 130:1076–1088PubMedCrossRef
13.
Roelofs RI, Hrushesky W, Rogin J et al (1984) Peripheral sensory neuropathy and cisplatin chemotherapy. Neurology 34:934–938PubMed
14.
Krarup-Hansen A, Rietz B, Krarup C et al (1999) Histology and platinum content of sensory ganglia and sural nerves in patients treated with cisplatin and carboplatin: an autopsy study. Neuropathol Appl Neurobiol 25:29–40PubMedCrossRef
15.
Cavaletti G, Tredici G, Petruccioli MG et al (2001) Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat. Eur J Cancer 37:2457–2463PubMedCrossRef
16.
Holmes J, Stanko J, Varchenko M et al (1998) Comparative neurotoxicity of oxaliplatin, cisplatin, and ormaplatin in a Wistar rat model. Toxicol Sci 46:342–351PubMed
17.
McKeage MJ, Hsu T, Screnci D et al (2001) Nuclear damage correlates with neurotoxicity induced by different platinum drugs. Br J Cancer 85:1219–1225PubMedCrossRef
18.
Jamieson SM, Liu J, Connor B et al (2005) Oxaliplatin causes selective atrophy of a subpopulation of dorsal root ganglion neurons without inducing cell loss. Cancer Chemother Pharmacol 56:391–399PubMedCrossRef
19.
Tomiwa K, Nolan C, Cavanagh JB (1986) The effects of cisplatin on rat spinal ganglia: a study by light and electron microscopy and by morphometry. Acta Neuropathol 69:295–308PubMedCrossRef
20.
Cavaletti G, Tredici G, Marmiroli P et al (1992) Morphometric study of the sensory neuron and peripheral nerve changes induced by chronic cisplatin (DDP) administration in rats. Acta Neuropathol 84:364–371PubMedCrossRef
21.
Cavaletti G, Fabbrica D, Minoia C et al (1998) Carboplatin toxic effects on the peripheral nervous system of the rat. Ann Oncol 9:443–447PubMedCrossRef
22.
Gregg RW, Molepo JM, Monpetit VJ et al (1992) Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity. J Clin Oncol 10:795–803PubMed
23.
Screnci D, McKeage MJ, Galettis P et al (2000) Relationships between hydrophobicity, reactivity, accumulation and peripheral nerve toxicity of a series of platinum drugs. Br J Cancer 82:966–972PubMedCrossRef
24.
Cavaletti G, Tredici G, Pizzini G et al (1990) Tissue platinum concentrations and cisplatin schedules. Lancet 336:1003PubMedCrossRef
25.
Screnci D, Er HM, Hambley TW et al (1997) Stereoselective peripheral sensory neurotoxicity of diaminocyclohexane platinum enantiomers related to ormaplatin and oxaliplatin. Br J Cancer 76:502–510PubMed
26.
Wang D, Lippard SJ (2005) Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 4:307–320PubMedCrossRef
27.
McDonald ES, Randon KR, Knight A et al (2005) Cisplatin preferentially binds to DNA in dorsal root ganglion neurons in vitro and in vivo: a potential mechanism for neurotoxicity. Neurobiol Dis 18:305–313PubMedCrossRef
28.
Meijer C, de Vries EG, Marmiroli P et al (1999) Cisplatin-induced DNA-platination in experimental dorsal root ganglia neuronopathy. Neurotoxicology 20:883–887PubMed
29.
Ta LE, Espeset L, Podratz J et al (2006) Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding. Neurotoxicology 27:992–1002PubMedCrossRef
30.
Dzagnidze A, Katsarava Z, Makhalova J et al (2007) Repair capacity for platinum-DNA adducts determines the severity of cisplatin-induced peripheral neuropathy. J Neurosci 27:9451–9457PubMedCrossRef
31.
Zhou B, Gitschier J (1997) hCTR1: a human gene for copper uptake identified by complementation in yeast. Proc Natl Acad Sci USA 94:7481–7486PubMedCrossRef
32.
Lee J, Petris MJ, Thiele DJ (2002) Characterization of mouse embryonic cells deficient in the ctr1 high affinity copper transporter. Identification of a Ctr1-independent copper transport system. J Biol Chem 277:40253–40259PubMedCrossRef
33.
Ishida S, Lee J, Thiele DJ et al (2002) Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci USA 99:14298–14302PubMedCrossRef
34.
Lin X, Okuda T, Holzer A et al (2002) The copper transporter CTR1 regulates cisplatin uptake in Saccharomyces cerevisiae. Mol Pharmacol 62:1154–1159PubMedCrossRef
35.
Holzer AK, Manorek GH, Howell SB (2006) Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin. Mol Pharmacol 70:1390–1394PubMedCrossRef
36.
Song IS, Savaraj N, Siddik ZH et al (2004) Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells. Mol Cancer Ther 2004:1543–1549
37.
Holzer AK, Varki NM, Le QT et al (2006) Expression of the human copper influx transporter 1 in normal and malignant human tissues. J Histochem Cytochem 54:1041–1049PubMedCrossRef
38.
Lee J, Prohaska JR, Dagenais SL et al (2000) Isolation of a murine copper transporter gene, tissue specific expression and functional complementation of a yeast copper transport mutant. Gene 254:87–96PubMedCrossRef
39.
Kuo YM, Zhou B, Cosco D et al (2001) The copper transporter CTR1 provides an essential function in mammalian embryonic development. Proc Natl Acad Sci USA 98:6836–6841PubMedCrossRef
40.
Karmy G, Carr PA, Yamamoto T et al (1991) Cytochrome oxidase immunohistochemistry in rat brain and dorsal root ganglia: visualization of enzyme in neuronal perikarya and in parvalbumin-positive neurons. Neuroscience 40:825–839PubMedCrossRef
41.
Rosenfeld JCS, James R (1997) Expression of superoxide dismutase following axotomy. Exp Neurol 147:37–47PubMedCrossRef
42.
Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2-rrCt method. Methods 25:402–408PubMedCrossRef
43.
Bergman E, Ulfhake B (1998) Loss of primary sensory neurons in the very old rat: neuron number estimates using the disector method and confocal optical sectioning. J Comp Neurol 396:211–222PubMedCrossRef
44.
Lawson SN, Harper AA, Harper EI et al (1984) A monoclonal antibody against neurofilament protein specifically labels a subpopulation of rat sensory neurones. J Compar Neurol 228:263–272CrossRef
45.
Lee J, Prohaska JR, Thiele DJ (2001) Essential role for mammalian copper transporter Ctr1 in copper homeostasis and embryonic development. Proc Natl Acad Sci USA 98:6842–6847PubMedCrossRef
46.
Holzer AK, Katano K, Klomp LW et al (2004) Cisplatin rapidly down-regulates its own influx transporter hCTR1 in cultured human ovarian carcinoma cells. Clin Cancer Res 10:6744–6749PubMedCrossRef
47.
Holzer AK, Howell SB (2006) The internalization and degradation of human copper transporter 1 following cisplatin exposure. Cancer Res 66:10944–10952PubMedCrossRef
48.
Waggoner DJ, Bartnikas TB, Gitlin JD (1999) The role of copper in neurodegenerative disease. Neurobiol Dis 6:221–230PubMedCrossRef
49.
Samimi G, Katano K, Holzer AK et al (2004) Modulation of the cellular pharmacology of cisplatin and its analogs by the copper exporters ATP7A and ATP7B. Mol Pharmacol 66:25–32PubMedCrossRef
50.
Komatsu M, Sumizawa T, Mutoh M et al (2000) Copper-transporting P-type adenosine triphosphatase (ATP7B) is associated with cisplatin resistance. Cancer Res 60:1312–1316PubMed
51.
Samimi G, Safaei R, Katano K et al (2004) Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells. Clin Cancer Res 10:4661–4669PubMedCrossRef
52.
Yonezawa A, Masuda S, Yokoo S et al (2006) Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1–3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther 319:879–886PubMedCrossRef
53.
Zhang S, Lovejoy KS, Shima JE et al (2006) Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res 66:8847–8857PubMedCrossRef
54.
Taniguchi K, Wada M, Kohno K et al (1996) A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. Cancer Res 56:4124–4129PubMed
55.
Ishikawa T, Ali-Osman F (1993) Glutathione-associated cis-diamminedichloroplatinum(II) metabolism and ATP-dependent efflux from leukemia cells. Molecular characterization of glutathione-platinum complex and its biological significance. J Biol Chem 268:20116–20125PubMed
Metadata
Title
Neuronal expression of copper transporter 1 in rat dorsal root ganglia: association with platinum neurotoxicity
Authors
Johnson J. Liu
Stephen M. F. Jamieson
Joshuan Subramaniam
Virginia Ip
Nancy N. Jong
Julian F. B. Mercer
Mark J. McKeage
Publication date
01-09-2009
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 4/2009
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-009-1017-6

Other articles of this Issue 4/2009

Cancer Chemotherapy and Pharmacology 4/2009 Go to the issue

Original Article

Characterization of highly stable liposomal and immunoliposomal formulations of vincristine and vinblastine

Original Article

Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)

Original Article

Carbonate and carbamate derivatives of 4-demethylpenclomedine as novel anticancer agents

Original Article

Phase II trial of S-1 in combination with gemcitabine for chemo-naïve patients with locally advanced or metastatic pancreatic cancer

Original Article

The microtubule-active antitumor compound TTI-237 has both paclitaxel-like and vincristine-like properties

Original Article

Indomethacin overcomes doxorubicin resistance by decreasing intracellular content of glutathione and its conjugates with decreasing expression of γ-glutamylcysteine synthetase via promoter activity in doxorubicin-resistant leukemia cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits